Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

Read everything here.Cancer Money Horoscope TodayYou will receive guidance from seniors at work, maintaining a notable ...

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

This decision expands the initial authorization within the European Union for the treatment of EoE in adults and adolescents, positioning Dupixent as the first and only medication approved for ...

If you’re down for an intimate culinary experience with room to soak it all in, check out The Turntable, 116 S. Washington St ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent (dupilumab) to be utilized in the treatment of ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...